Proteau Philip J
Department of Pharmaceutical Sciences, College of Pharmacy, Pharmacy Building, Room 203, Oregon State University, Corvallis 97331-3507, USA.
Bioorg Chem. 2004 Dec;32(6):483-93. doi: 10.1016/j.bioorg.2004.08.004.
The methylerythritol phosphate pathway to isoprenoids, an alternate biosynthetic route present in many bacteria, algae, plants, and the malarial parasite Plasmodium falciparum, has become an attractive target for the development of new antimalarial and antibacterial compounds. The second enzyme in this pathway, 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR; EC 1.1.1.267), has been shown to be the molecular target for fosmidomycin, a promising antimalarial drug. This enzyme converts 1-deoxy-D-xylulose 5-phosphate (DXP) into the branched compound 2-C-methyl-D-erythritol 4-phosphate (MEP). The transformation of DXP into MEP requires an isomerization, followed by a NADPH-dependent reduction. The discovery of DXR, its subsequent characterization, and the identification of inhibitors will be presented.
通向类异戊二烯的甲基赤藓糖醇磷酸途径是许多细菌、藻类、植物以及疟原虫恶性疟原虫中存在的一条替代生物合成途径,已成为开发新型抗疟和抗菌化合物的一个有吸引力的靶点。该途径中的第二种酶,1-脱氧-D-木酮糖 5-磷酸还原异构酶(DXR;EC 1.1.1.267),已被证明是磷霉素的分子靶点,磷霉素是一种有前景的抗疟药物。这种酶将 1-脱氧-D-木酮糖 5-磷酸(DXP)转化为分支化合物 2-C-甲基-D-赤藓糖醇 4-磷酸(MEP)。DXP 向 MEP 的转化需要异构化,随后是 NADPH 依赖的还原反应。本文将介绍 DXR 的发现、其后续特性以及抑制剂的鉴定。